Exelixis (EXEL) Competitor Comparison
We are evaluating the key criteria listed to compare Exelixis (EXEL) against its competitors in the Biotechnology industry.
Market Capitalization
29 / 368Gross Profits
9 / 278Total Revenue
12 / 300EBITDA
20 / 337Free Cashflow
256 / 352Quick Ratio
241 / 357Earnings per Share
17 / 359Dividend yield
0 / 6Total Cash
20 / 358Performance 3 years
49 / 368Performance 5 years
64 / 368Performance 10 years
3 / 368Linearity 3 years
206 / 368Linearity 5 years
251 / 368Linearity 10 years
358 / 367Total Rank
121 / 368Dividend Rank
124 / 368Valuation Rank
114 / 368Piotroski Rank
114 / 368Muliplier Rank
341 / 368Market Capitalization - EXEL ranking 29 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.